SCHEMBL4351357

SCHEMBL4351357

Cc1nn(C)cc1CC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
LMNA P02545 2/20 0.44
TSHR P16473 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 4/20 0.43
USP2 O75604 1/20 0.43
NPC1 O15118 3/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
HPGD P15428 1/20 0.42
GAA P10253 2/20 0.41
FEN1 P39748 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
HTT P42858 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4208861 0.83 RAB9A (0.43) RAB9ASMN1; SMN2LMNATSHRALDH1A1
SCHEMBL5106211 0.82 AKR1B1 (0.41) RAB9ASMN1; SMN2LMNATSHRL3MBTL1
SCHEMBL13732223 0.78 RAB9A (0.59) RAB9ASMN1; SMN2LMNATSHRALDH1A1
SCHEMBL12293927 0.77
SCHEMBL4354136 0.77 L3MBTL1 (0.41) LMNAL3MBTL1ALDH1A1MEN1MAPT
SCHEMBL15528666 0.76 PTGDR2 (0.40) SMN1; SMN2L3MBTL1ALDH1A1MAPTKDM4E
SCHEMBL3269319 0.75
SCHEMBL4597012 0.74 L3MBTL1 (0.49) RAB9ASMN1; SMN2LMNATSHRL3MBTL1
SCHEMBL12985893 0.74 EPHX2 (0.44) LMNATSHRALDH1A1HPGDKDM4E
SCHEMBL1194424 0.74 KDM4E (0.66) RAB9ASMN1; SMN2LMNAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188075-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS THE BROAD INSTITUTE, INC. 2025-06-12 US disclosed
EP-4469457-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS The Broad Institute Inc. (US) 2024-12-04 EP disclosed
WO-2023147015-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS THE BROAD INSTITUTE, INC. (US) 2023-08-03 WO disclosed
CN-105086344-A Resist composition and method for manufacturing conductive pattern using resist composition TOKYO OHKA KOGYO CO LTD 2015-11-25 CN disclosed
US-7614145-B2 Method for manufacturing multilayer circuit board and resin base material ZEON CORPORATION (JP) 2009-11-10 US disclosed
CN-100496195-C Mulitilayer circuit board, resin base material, and its production method ZEON CORP (JP) 2009-06-03 CN disclosed
CN-100383278-C Partial plating method, partially-plated resin base, method for manufacturing multilayer circuit board ZEON CORP (JP) 2008-04-23 CN disclosed
US-20050175824-A1 Method for forming multilayer circuit structure and base having multilayer circuit structure ZEON CORPORATION (JP) 2005-08-11 US disclosed
US-20050153059-A1 Partial plating method, partially-plated resin base, method for manufacturing multilayered circuit board ZEON CORPORATION (JP) 2005-07-14 US disclosed
CN-1639384-A Partial plating method, partially-plated resin base, method for manufacturing multilayer circuit board ZEON CORP (JP) 2005-07-13 CN disclosed
US-20040237295-A1 Multilayer circuit board and resin base material, and its production method ZEON CORPORATION (JP) 2004-12-02 US disclosed
CN-1552174-A Mulitilayer circuit board, resin base material, and its production method �ձ�������ʽ���� 2004-12-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188075-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS CSNK1A1, CSNK2A1, CSNK1A1L RAB9A 1116/4885SMN1; SMN2 2952/4885LMNA 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.